Eyenovia, Inc. Plans New Public Offering
Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof) in a best efforts offering. All of the securities to be sold in the offering are to be offered by Eyenovia. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Use of Proceeds
The Company intends to use the net proceeds from this offering to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, and for working capital and general corporate purposes, which may include the repayment of a portion of existing indebtedness.
Placement Agent
Dawson James Securities, Inc. is the sole placement agent for the offering.
Regulatory Filings
The offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement and accompanying prospectus. The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website.
About Eyenovia, Inc.
Eyenovia, Inc. is an ophthalmic technology company commercializing Mydcombi for mydriasis, Clobetasol Propionate Ophthalmic Suspension for postsurgical inflammation and pain, and developing the Optejet device for pediatric progressive myopia and other indications.
Contact Information
Eyenovia Contact:
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
Frequently Asked Questions
What is the purpose of Eyenovia's public offering?
The public offering is intended to fund commercialization activities and clinical studies for Eyenovia's products.
Who is the placement agent for the offering?
Dawson James Securities, Inc. serves as the sole placement agent for the offering.
How will Eyenovia use the funds from the offering?
The proceeds will support various initiatives, including product commercialization, clinical studies, and operational costs.
Where can I find more information about the offering?
More information will be available in the prospectus supplement that Eyenovia will file with the SEC.
What products does Eyenovia focus on?
Eyenovia specializes in ophthalmic products, including Mydcombi and Clobetasol Propionate, as well as developing the Optejet device.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.